The Haemato-Oncology section provides genetic and genomic analysis of samples from patients with a range of haematological malignancies and disorders and lymphoproliferative conditions. The results obtained assist in diagnosis and classification, provide prognostic information for use in risk stratification, can direct therapeutic choice, and enable assessment of residual disease status post-treatment and/or post-transplant. We are a constituent laboratory of the West Midlands SIHMDS (MIRHO) and host of the Central England Haemato-Oncology and Oncology Research Biobank (CEHRB), and participate in the 100,000 Genomes Project.
The section processes over 20,000 bone marrow and blood samples per annum, utilising a range of cytogenetic (G-band Karyotyping, FISH) and molecular genetic techniques including Next Generation Sequencing (NGS panels), SNP arrays, Droplet Digital PCR (ddPCR), Real-Time Quantitative PCR (RTqPCR), RT-PCR, Fragment Analysis, MLPA and Sanger Sequencing.
Further information about some of our recently introduced tests is available here:
- NGS panel for MPN[pdf] 156KB
- NGS panel for MDS/AML[pdf] 183KB
- SNP arrays for MDS [pdf] 325KB
- CIS (breakage) Information Sheet [pdf] 103KB
Recent communications with our service users are available here:
- Guidance for genetic testing during the COVID-19 outbreak v240320 [pdf] 511KB
- Position statement on the introduction of whole-genome sequencing for Haemato-Oncology [pdf] 119KB
- Turnaround times for Haemato-oncology genomic testing services [pdf] 397KB
- Rapid FLT3-mutation analysis in the context of midostaurin treatment - February 2019 [docx] 1MB
- User update letter October 2017 [pdf] 258KB
- MDS referral triaging and introduction of SNP arrays - January 2018 [pdf] 90KB
- Conversion of CML BCR-ABL1 RQ-PCR results to the International Scale March 2018 [pdf] 223KB
Wessex referral form for rapid FLT3 mutation analysis